Achieve Life Sciences, Inc. (ACHV) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 2 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

9
Achieve Life Sciences (ACHV) Q1 2026: $180M Financing Secured, U.S. Manufacturing Shift De-Risks Commercial Launch
May 12, 2026
10
Achieve Life Sciences (ACHV) Q4 2025: U.S. Manufacturing Shift Secures Launch Path for First New Smoking Cessation Drug in 20 Years
March 24, 2026
9
Achieve Life Sciences (ACHV) Q3 2025: FDA Priority Voucher Cuts Vaping Launch Timeline by 8 Months
November 06, 2025
5
Achieve Life Sciences (ACHV) Q2 2025: $49M Capital Raise Primes Cytisinicline Launch Path
August 07, 2025
8
Achieve Life Sciences (ACHV) Q1 2025: Advancing Toward NDA Submission with Over 100 Patients in One-Year Safety Study
May 13, 2025
8
Achieve Life Sciences (ACHV) Q4 2024: Preparing for Pivotal NDA Submission with $34.4M Cash Runway Into Q3 2025
March 11, 2025
Achieve Life Sciences (ACHV) Q3 2024: $20M SVB Loan Refinancing Extends Runway for NDA Push
November 07, 2024
Achieve Life Sciences (ACHV) Q2 2024: FDA Breakthrough Status Accelerates Vaping Indication Path
August 13, 2024
Achieve Life Sciences (ACHV) Q1 2024: $124M Financing Secured as NDA Pathway Clears for Cytosinicline
May 09, 2024
Achieve Life Sciences (ACHV) Q4 2023: $124M Financing Secured to Accelerate Cytisinicline NDA Path
March 28, 2024
Achieve Life Sciences (ACHV) Q3 2023: Operating Loss Cut 46% as Cytisinicline Nears NDA Milestone
November 09, 2023
Achieve Life Sciences (ACHV) Q2 2023: ORCA3 Delivers 4–6x Quit Odds, NDA Path and Partnering in Focus
August 15, 2023
Achieve Life Sciences (ACHV) Q1 2023: Cytisinicline Triples Vaping Quit Odds, Setting Up NDA Milestone
May 09, 2023
Achieve Life Sciences (ACHV) Q4 2022: $17.9M Capital Infusion Extends Runway as Dual Phase 3 Readouts Approach
March 16, 2023

Browse all companies